CIBC Asset Management Inc Grows Stake in Abbott Laboratories $ABT

Key Points

• CIBC Asset Management increased its stake in Abbott Laboratories by 10.6% in the fourth quarter, buying 61,369 additional shares and bringing its total holding to 640,677 shares valued at about $80.2 million.
• Abbott reported better-than-expected quarterly results, with earnings per share of $1.15 and revenue of $11.16 billion, while also issuing FY2026 EPS guidance of $5.38 to $5.58.
• Several analysts cut price targets on ABT, but the stock still carries a “Moderate Buy” consensus rating with an average target price of $119.09; insiders also bought shares recently, including a director and the CFO.

CIBC Asset Management Inc boosted its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 10.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 640,677 shares of the healthcare product maker's stock after purchasing an additional 61,369 shares during the quarter. CIBC Asset Management Inc's holdings in Abbott Laboratories were worth $80,191,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in ABT. Brighton Jones LLC increased its position in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after purchasing an additional 4,755 shares during the period. Sivia Capital Partners LLC increased its position in Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker's stock valued at $648,000 after purchasing an additional 162 shares during the period. United Bank increased its position in Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker's stock valued at $3,945,000 after purchasing an additional 2,001 shares during the period. Main Street Financial Solutions LLC increased its position in Abbott Laboratories by 13.6% during the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker's stock valued at $1,618,000 after purchasing an additional 1,428 shares during the period. Finally, Canada Pension Plan Investment Board increased its position in Abbott Laboratories by 25.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker's stock valued at $195,267,000 after purchasing an additional 292,547 shares during the period. Hedge funds and other institutional investors own 75.18% of the company's stock.

Abbott Laboratories Stock Down 0.9%

Shares of ABT stock opened at $87.02 on Wednesday. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $139.06. The stock's fifty day moving average price is $94.07 and its 200 day moving average price is $110.31. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The company has a market cap of $151.57 billion, a price-to-earnings ratio of 24.38, a price-to-earnings-growth ratio of 1.46 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same period in the previous year, the business earned $1.09 EPS. The firm's revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, research analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

ABT has been the topic of a number of analyst reports. Stifel Nicolaus cut their price target on Abbott Laboratories from $145.00 to $120.00 and set a "buy" rating on the stock in a report on Friday, April 17th. Benchmark cut their price target on Abbott Laboratories from $145.00 to $120.00 and set a "buy" rating on the stock in a report on Friday, April 17th. Raymond James Financial cut their price target on Abbott Laboratories from $130.00 to $115.00 and set an "outperform" rating on the stock in a report on Friday, April 17th. Jefferies Financial Group cut their price target on Abbott Laboratories from $145.00 to $135.00 and set a "buy" rating on the stock in a report on Friday, April 17th. Finally, Barclays cut their price target on Abbott Laboratories from $144.00 to $143.00 and set an "overweight" rating on the stock in a report on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company's stock. According to MarketBeat.com, Abbott Laboratories has an average rating of "Moderate Buy" and an average target price of $119.09.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of the company's stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Philip P. Boudreau bought 2,200 shares of the company's stock in a transaction on Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by insiders.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.